Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cancer drug alter Metformin's effects? a trial investigates

NCT ID NCT07753252

Not yet recruiting Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This Phase 1 study in healthy adults aims to find out whether sevabertinib, an experimental cancer drug, changes how the body processes metformin, a common diabetes medication. Researchers suspect sevabertinib might block kidney transporters that help remove metformin from the body. Participants will receive metformin alone, then again after taking sevabertinib for several days, allowing scientists to compare drug levels and assess safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sevabertinib (BAY 2927088) and metformin
What this could lead to
If sevabertinib is found to affect metformin levels, it could guide dosing recommendations when both drugs are used together, potentially improving safety and effectiveness.
What could go wrong
This is an early-phase study in a small group of healthy volunteers, so results may not reflect real-world patients. The interaction may be minimal or not clinically significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Clinical Pharmacology of Miami - Oncology

    Miami, Florida, 33172, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.